Eledon Q2 net loss $31.6M; cash $88.8M; Phase 3 kidney trial on track

Eledon Pharmaceuticals, Inc.

Cash $88.8M at June 30, 2026 vs $133.3M at Dec 31, 2025; expected to fund ops into Q2 2027.
Q2 net loss $31.6M ($0.27/share) vs $11.2M ($0.13) prior year; ex-warrant changes, loss $22.0M vs $23.5M.
FDA End-of-Phase 2 meeting supports Phase 3 kidney transplant trial of tegoprubart; ~600 patients, late 2026 start.
BESTOW 18-month data: eGFR ~12 mL/min higher vs tacrolimus (74 vs 61); no BPAR after 6 months in tegoprubart arm.
Islet cell study: all 12 T1D patients insulin-independent, mean HbA1c ~5.4%; Natera Prospera partnership for Phase 3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.